Lung cancer: When does post-operative radiotherapy not provide a benefit?
SP-0360
Abstract
Lung cancer: When does post-operative radiotherapy not provide a benefit?
Authors: Antonin Levy1, Olaf Mercier2, Angela Botticella1, Aicha Traore-Diallo1, Céline Berthold1, Guillaume Auzac1, Aurélie Bardet3, Cécile Le Péchoux4
1Gustave Roussy, Radiation Oncology, Villejuif, France; 2Marie-Lannelongue, Thoracic and Vascular Surgery, Le Plessis-Robinson, France; 3Gustave Roussy, Statistics, Villejuif, France; 4Gustave Roussy, Radiation Oncology, Villejuif , France
Show Affiliations
Hide Affiliations
Abstract Text
Patients with locally advanced resected non-small cell lung cancer (NSCLC) are at high risk of relapse. Although platinum-based adjuvant chemotherapy has become standard, the role of postoperative radiotherapy (PORT) is controversial, especially in stage IIIA pN2 patients. Two prospective randomized phase III studies evaluating modern PORT in patients with completely resected stage IIIA-N2 NSCLC who received (neo)adjuvant chemotherapy have been reported: the European Lung ART trial (n=501 patient) and the single-centre Chinese PORT-C trial (n=364 patients). No difference in disease-free survival (DFS) at 3 years was found, these two trials being therefore negative for their primary endpoint. Overall survival (OS) was also not different between the groups in both trials. Differences between studies will be highlighted. An improvement in locoregional control (decreased rate of mediastinal relapse) was however shown in both trials. Ongoing analyses could identify a subgroup of patients for whom PORT could be considered.